XML 26 R16.htm IDEA: XBRL DOCUMENT v3.26.1
Business Segment:
 3 Months Ended
Mar. 31, 2026
Business Segment:  
Business Segment:

Note 10 – Business Segment:

The Company operates in one business segment, which consists of research and development activities related to developing therapeutics for neurodegenerative diseases. This determination is consistent with the financial information regularly provided to the Company’s chief operating decision makers (“CODM”). The Company’s CODM for the research and development business is its Chief Medical Officer, in conjunction with the Executive Chairman of the Board, who reviews and evaluates net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

The Company’s cryptocurrency treasury strategy is managed by the Executive Chairman of the Board in conjunction with the Company’s Chairman of the Audit Committee of the Board and does not represent a separate business segment.

In addition to the significant expense categories included within net loss presented on the Company’s Condensed Condensed Consolidated Statements of Comprehensive Income, the following table disaggregates the components of research and development expenses:

​

​

​

​

​

​

​

​

​

​

​

For the Three Months Ended March 31, 

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

External clinical development expenses

​

$

10,352

​

$

26,191

​

Personnel related and stock-based compensation

​

 

2,512

​

 

12,825

​

Other research and development expenses

​

 

15,736

​

 

21,800

​

Total research and development expenses

​

$

28,600

​

$

60,816

​

​